The role of advanced glycation end products in retinal ageing and disease

Biochimica et Biophysica Acta - General Subjects

Volumn 1790, Issue 10, 2009, Pages 1109-1116

  Glenn, Josephine V ^a   Stitt, Alan W ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Advanced glycation end product; Ageing; AMD; RPE

Indexed keywords

1 (5 AMINO 5 CARBOXYPENTYL) 4 (5 AMINO 5 CARBOXYPENTYLAMINO) 3 HYDROXY 2,3 DIHYDROPYRIDINIUM; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR ANTIBODY; AGENTS ACTING ON THE EYE; ALAGEBRIUM; AMINOGUANIDINE; GLUCOSEPANE; PHENACYLTHIAZOLIUM BROMIDE; PYRIDOXAMINE; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; BLINDNESS; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG MECHANISM; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATION; NERVE DEGENERATION; NONHUMAN; PATHOPHYSIOLOGY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SIGNAL TRANSDUCTION; VASCULAR DISEASE; VITREOUS BODY;

AGING; ANIMALS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MACULAR DEGENERATION; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; RECEPTORS, IMMUNOLOGIC; RETINA; RETINAL PIGMENT EPITHELIUM;

EID: 69949085013     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2009.04.016     Document Type: Review

References (131)

1. Strehler B.L. Further studies on the thermally induced aging of Drosophila melanogaster. J. Gerontol. 17 (1962) 347-352
2. Szweda P.A., Camouse M., Lundberg K.C., Oberley T.D., and Szweda L.I. Aging, lipofuscin formation, and free radical-mediated inhibition of cellular proteolytic systems. Ageing Res. Rev. 2 (2003) 383-405
3. Yin D., and Chen K. The essential mechanisms of aging: irreparable damage accumulation of biochemical side-reactions. Exp. Gerontol. 40 (2005) 455-465
4. Maeda A., Crabb J.W., and Palczewski K. Microsomal glutathione S-transferase 1 in the retinal pigment epithelium: protection against oxidative stress and a potential role in aging. Biochemistry 44 (2005) 480-489
5. Liang F.Q., and Godley B.F. Oxidative stress-induced mitochondrial DNA damage in human retinal pigment epithelial cells: a possible mechanism for RPE aging and age-related macular degeneration. Exp. Eye Res. 76 (2003) 397-403
6. Sebag J. Anomalous posterior vitreous detachment: a unifying concept in vitreo-retinal disease. Graefes Arch. Clin. Exp. Ophthalmol. 242 (2004) 690-698
7. Sebag J. Ageing of the vitreous. Eye 1 Pt 2 (1987) 254-262
8. Nduaguba C., and Lee R.K. Glaucoma screening: current trends, economic issues, technology, and challenges. Curr. Opin. Ophthalmol. 17 (2006) 142-152
9. Harwerth R.S., Wheat J.L., and Rangaswamy N.V. Age-related losses of retinal ganglion cells and axons. Investig. Ophthalmol. Vis. Sci. 49 (2008) 4437-4443
10. Parikh R.S., Parikh S.R., Sekhar G.C., et al. Normal age-related decay of retinal nerve fiber layer thickness. Ophthalmology 114 (2007) 921-926
11. Boland M.V., and Quigley H.A. Risk factors and open-angle glaucoma: classification and application. J. Glaucoma 16 (2007) 406-418
12. Allingham R.R., Liu Y., and Rhee D.J. The genetics of primary open-angle glaucoma: a review. Exp. Eye Res. 88 4 (2008) 837-844
13. DellaCroce J.T., and Vitale A.T. Hypertension and the eye. Curr. Opin. Ophthalmol. 19 (2008) 493-498
14. Pache M., and Flammer J. A sick eye in a sick body? Systemic findings in patients with primary open-angle glaucoma. Surv. Ophthalmol. 51 (2006) 179-212
15. Godley B.F., Shamsi F.A., Liang F.Q., et al. Blue light induces mitochondrial DNA damage and free radical production in epithelial cells. J. Biol. Chem. 280 (2005) 21061-21066
16. Starita C., Hussain A.A., Pagliarini S., and Marshall J. Hydrodynamics of ageing Bruch's membrane: implications for macular disease. Exp. Eye. Res. 62 (1996) 565-572
17. Binder S., Stanzel B.V., Krebs I., and Glittenberg C. Transplantation of the RPE in AMD. Prog. Retin. Eye Res. 26 (2007) 516-554
18. Ambati J., Ambati B.K., Yoo S.H., Ianchulev S., and Adamis A.P. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv. Ophthalmol. 48 (2003) 257-293
19. Boulton M., and Dayhaw-Barker P. The role of the retinal pigment epithelium: topographical variation and ageing changes. Eye 15 (2001) 384-389
20. Boulton M., Roanowska M., and Wess T. Ageing of the retinal pigment epithelium: implications for transplantation. Graefes Arch. Clin. Exp. Ophthalmol. 242 (2004) 76-84
21. Bird A.C., Bressler N.M., Bressler S.B., et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv. Ophthalmol. 39 (1995) 367-374
22. Schutt F., Bergmann M., Holz F.G., and Kopitz J. Proteins modified by malondialdehyde, 4-hydroxynonenal, or advanced glycation end products in lipofuscin of human retinal pigment epithelium. Investig. Ophthalmol. Vis. Sci. 44 (2003) 3663-3668
23. de Jong P.T. Age-related macular degeneration. N. Engl. J. Med. 355 (2006) 1474-1485
24. Klein R., Klein B.E., Tomany S.C., Meuer S.M., and Huang G.H. Ten-year incidence and progression of age-related maculopathy: the Beaver Dam eye study. Ophthalmology 109 (2002) 1767-1779
25. Beatty S., Koh H., Phil M., Henson D., and Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv. Ophthalmol. 45 (2000) 115-134
26. Hjelmeland L.M., Cristofolo V.J., Funk W., Rakoczy E., and Katz M.L. Senescence of the retinal pigment epithelium. Mol. Vis. 5 (1999) 33
27. Glenn J.V., Mahaffy H., Wu K., et al. Advanced glycation end product (AGE) accumulation on Bruch's membrane: links to age-related RPE dysfunction. Investig. Ophthalmol. Vis. Sci. 50 (2009) 441-451
28. Hageman G.S., Anderson D.H., Johnson L.V., et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 7227-7232
29. Klein R.J., Zeiss C., Chew E.Y., et al. Complement factor H polymorphism in age-related macular degeneration. Science 308 (2005) 385-389
30. Seitsonen S., Jarvela I., Meri S., et al. Complement factor H Y402H polymorphism and characteristics of exudative age-related macular degeneration lesions. Acta Ophthalmol. 86 (2008) 390-394
31. Ding X., Patel M., and Chan C.C. Molecular pathology of age-related macular degeneration. Prog. Retin. Eye Res. 28 1 (2009) 1-18
32. Lommatzsch A., Hermans P., Muller K.D., et al. Are low inflammatory reactions involved in exudative age-related macular degeneration? Morphological and immunohistochemical analysis of AMD associated with basal deposits. Graefes Arch. Clin. Exp. Ophthalmol. 246 (2008) 803-810
33. Kijlstra A., La Heij E., and Hendrikse F. Immunological factors in the pathogenesis and treatment of age-related macular degeneration. Ocul. Immunol. Inflamm. 13 (2005) 3-11
34. Monnier V.M., Sell D.R., Nagaraj R.H., et al. Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes 41 Suppl 2 (1992) 36-41
35. Thorpe S.R., and Baynes J.W. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 25 (2003) 275-281
36. Goldin A., Beckman J.A., Schmidt A.M., and Creager M.A. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114 (2006) 597-605
37. Thornalley P.J., Langborg A., and Minhas H.S. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem. J. 344 Pt 1 (1999) 109-116
38. Glomb M.A., and Lang G. Isolation and characterization of glyoxal-arginine modifications. J. Agric. Food. Chem. 49 (2001) 1493-1501
39. Kuhla B., Luth H.J., Haferburg D., et al. Methylglyoxal, glyoxal, and their detoxification in Alzheimer's disease. Ann. N.Y. Acad. Sci. 1043 (2005) 211-216
40. Shinohara M., Thornalley P.J., Giardino I., et al. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J. Clin. Invest. 101 (1998) 1142-1147
41. Morcos M., Du X., Pfisterer F., et al. Glyoxalase-1 prevents mitochondrial protein modification and enhances lifespan in Caenorhabditis elegans. Aging Cell 7 (2008) 260-269
42. Schmidt A.M., Yan S.D., Yan S.F., and Stern D.M. The biology of the receptor for advanced glycation end products and its ligands. Biochim. Biophys. Acta 1498 (2000) 99-111
43. Yan S.F., D'Agati V., Schmidt A.M., and Ramasamy R. Receptor for advanced glycation endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging. Curr. Mol. Med. 7 (2007) 699-710
44. Neeper M., Schmidt A.M., Brett J., et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267 (1992) 14998-15004
45. Kislinger T., Fu C., Huber B., et al. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem. 274 (1999) 31740-31749
46. Hori O., Brett J., Slattery T., et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 270 (1995) 25752-25761
47. Chaney M.O., Stine W.B., Kokjohn T.A., et al. RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling. Biochim. Biophys. Acta 1741 (2005) 199-205
48. Hofmann M.A., Drury S., Fu C., et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97 (1999) 889-901
49. Takeuchi M., and Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr. Pharm. Des. 14 (2008) 973-978
50. Ehlermann P., Eggers K., Bierhaus A., et al. Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc. Diabetol. 5 (2006) 6
51. Lohwasser C., Neureiter D., Weigle B., Kirchner T., and Schuppan D. The receptor for advanced glycation end products is highly expressed in the skin and upregulated by advanced glycation end products and tumor necrosis factor-alpha. J. Invest. Dermatol. 126 (2006) 291-299
52. Gao Z.Q., Yang C., Wang Y.Y., et al. RAGE upregulation and nuclear factor-kappaB activation associated with ageing rat cardiomyocyte dysfunction. Gen. Physiol. Biophys. 27 (2008) 152-158
53. Semba R.D., Ferrucci L., Fink J.C., et al. Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women. Am. J. Kidney Dis. 53 1 (2009) 51-58
54. Kaji Y., Usui T., Oshika T., et al. Advanced glycation end products in diabetic corneas. Investig. Ophthalmol Vis Sci 41 (2000) 362-368
55. Malik N.S., Moss S.J., Ahmed N., et al. Ageing of the human corneal stroma: structural and biochemical changes. Biochim. Biophys. Acta 1138 (1992) 222-228
56. Amano S., Kaji Y., Oshika T., et al. Advanced glycation end products in human optic nerve head. Br. J. Ophthalmol. 85 (2001) 52-55
57. Cheng R., Lin B., and Ortwerth B.J. Rate of formation of AGEs during ascorbate glycation and during aging in human lens tissue. Biochim. Biophys. Acta 1587 (2002) 65-74
58. Sebag J., Buckingham B., Charles M.A., and Reiser K. Biochemical abnormalities in vitreous of humans with proliferative diabetic retinopathy. Arch. Ophthalmol. 110 (1992) 1472-1476
59. Stitt A.W., Moore J.E., Sharkey J.A., et al. Advanced glycation end products in vitreous: structural and functional implications for diabetic vitreopathy. Investig. Ophthalmol. Vis. Sci. 39 (1998) 2517-2523
60. Katsumura C., Sugiyama T., Nakamura K., et al. Effects of advanced glycation end products on hyaluronan photolysis: a new mechanism of diabetic vitreopathy. Ophthalmic Res. 36 (2004) 327-331
61. Sebag J. Abnormalities of human vitreous structure in diabetes. Graefes Arch. Clin. Exp. Ophthalmol. 231 (1993) 257-260
62. Gardiner T.A., Anderson H.R., and Stitt A.W. Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes. J. Pathol. 201 (2003) 328-333
63. Hammes H.P., Alt A., Niwa T., et al. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia 42 (1999) 728-736
64. Murata T., Nagai R., Ishibashi T., et al. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia 40 (1997) 764-769
65. Schalkwijk C.G., Ligtvoet N., Twaalfhoven H., et al. Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries. Diabetes 48 (1999) 2446-2453
66. Stitt A.W., Li Y.M., Gardiner T.A., et al. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am. J. Pathol. 150 (1997) 523-531
67. Hammes H.P., Brownlee M., Edelstein D., et al. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 37 (1994) 32-35
68. Stitt A.W., Jenkins A.J., and Cooper M.E. Advanced glycation end products and diabetic complications. Expert Opin. Investig. Drugs 11 (2002) 1205-1223
69. Bhatwadekar A., and Stitt A.W. AGEs and RAGE inhibitors in the treatment of diabetic retinopathy. Expert Rev. Ophthalmol. 2 (2007) 105-120
70. Leske M.C., Heijl A., Hussein M., et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch. Ophthalmol. 121 (2003) 48-56
71. Albon J., Karwatowski W.S., Avery N., Easty D.L., and Duance V.C. Changes in the collagenous matrix of the aging human lamina cribrosa. Br. J. Ophthalmol. 79 (1995) 368-375
72. Albon J., Purslow P.P., Karwatowski W.S., and Easty D.L. Age related compliance of the lamina cribrosa in human eyes. Br. J. Ophthalmol. 84 (2000) 318-323
73. Ino-ue M., Ohgiya N., and Yamamoto M. Effect of aminoguanidine on optic nerve involvement in experimental diabetic rats. Brain Res. 800 (1998) 319-322
74. Tezel G., Luo C., and Yang X. Accelerated aging in glaucoma: immunohistochemical assessment of advanced glycation end products in the human retina and optic nerve head. Investig. Ophthalmol. Vis. Sci. 48 (2007) 1201-1211
75. Bazan N.G. Metabolism of phospholipids in the retina. Vis. Res. 22 (1982) 1539-1548
76. Januszewski A.S., Alderson N.L., Metz T.O., Thorpe S.R., and Baynes J.W. Role of lipids in chemical modification of proteins and development of complications in diabetes. Biochem. Soc. Trans. 31 (2003) 1413-1416
77. Howes K.A., Liu Y., Dunaief J.L., et al. Receptor for advanced glycation end products and age-related macular degeneration. Investig. Ophthalmol. Vis. Sci. 45 (2004) 3713-3720
78. Handa J.T., Verzijl N., Matsunaga H., et al. Increase in the advanced glycation end product pentosidine in Bruch's membrane with age. Investig. Ophthalmol. Vis. Sci. 40 (1999) 775-779
79. Yamada Y., Ishibashi K., Bhutto A., et al. The expression of advanced glycation endproduct receptors in rpe cells associated with basal deposits in human maculas. Exp. Eye Res. 82 (2006) 840-848
80. Ishibashi T., Murata T., Hangai M., et al. Advanced glycation end products in age-related macular degeneration. Arch. Ophthalmol. 116 (1998) 1629-1632
81. Swamy-Mruthinti S., Miriam K.C., Kumar S.K., et al. Immunolocalization and quantification of advanced glycation end products in retinal neovascular membranes and serum: a possible role in ocular neovascularization. Curr. Eye Res. 25 (2002) 139-145
82. Rumble J.R., Cooper M.E., Soulis T., et al. Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products. J. Clin. Invest. 99 (1997) 1016-1027
83. Handa J.T., Reiser K.M., Matsunaga H., and Hjelmeland L.M. The advanced glycation endproduct pentosidine induces the expression of PDGF-B in human retinal pigment epithelial cells. Exp. Eye Res. 66 (1998) 411-419
84. Kobayashi S., Nomura M., Nishioka T., et al. Overproduction of N(epsilon)-(carboxymethyl)lysine-induced neovascularization in cultured choroidal explant of aged rat. Biol. Pharm. Bull. 30 (2007) 133-138
85. Zhou J., Cai B., Jang Y.P., et al. Mechanisms for the induction of HNE- MDA- and AGE-adducts, RAGE and VEGF in retinal pigment epithelial cells. Exp. Eye Res. 80 (2005) 567-580
86. Crabb J.W., Miyagi M., Gu X., et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 14682-14687
87. Gu X., Meer S.G., Miyagi M., et al. Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration. J. Biol. Chem. 278 (2003) 42027-42035
88. Ebrahem Q., Renganathan K., Sears J., et al. Carboxyethylpyrrole oxidative protein modifications stimulate neovascularization: implications for age-related macular degeneration. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 13480-13484
89. Cingolani C., Rogers B., Lu L., et al. Retinal degeneration from oxidative damage. Free Radic. Biol. Med. 40 (2006) 660-669
90. Shen J.K., Dong A., Hackett S.F., et al. Oxidative damage in age-related macular degeneration. Histol. Histopathol. 22 (2007) 1301-1308
91. Catala A. An overview of lipid peroxidation with emphasis in outer segments of photoreceptors and the chemiluminescence assay. Int. J. Biochem. Cell Biol. 38 (2006) 1482-1495
92. Esterbauer H., Schaur R.J., and Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 11 (1991) 81-128
93. Chakravarthy U., Augood C., Bentham G.C., et al. Cigarette smoking and age-related macular degeneration in the EUREYE Study. Ophthalmology 114 (2007) 1157-1163
94. Smith W., Assink J., Klein R., et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology 108 (2001) 697-704
95. Khan J.C., Thurlby D.A., Shahid H., et al. Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br. J. Ophthalmol. 90 (2006) 75-80
96. Ethen C.M., Reilly C., Feng X., Olsen T.W., and Ferrington D.A. Age-related macular degeneration and retinal protein modification by 4-hydroxy-2-nonenal. Investig. Ophthalmol. Vis. Sci. 48 (2007) 3469-3479
97. Crabb J.W., O'Neil J., Miyagi M., West K., Hoff H.F., and Hydroxynonenal inactivates cathepsin B. by forming Michael adducts with active site residues. Protein Sci. 11 (2002) 831-840
98. Fernandes A.F., Zhou J., Zhang X., et al. Oxidative inactivation of the proteasome in retinal pigment epithelial cells. A potential link between oxidative stress and up-regulation of interleukin-8. J. Biol. Chem. 283 (2008) 20745-20753
99. Kapphahn R.J., Bigelow E.J., and Ferrington D.A. Age-dependent inhibition of proteasome chymotrypsin-like activity in the retina. Exp. Eye Res. 84 (2007) 646-654
100. Schmid K., Haslbeck M., Buchner J., and Somoza V. Induction of heat shock proteins and the proteasome system by casein-N epsilon-(carboxymethyl)lysine and N epsilon-(carboxymethyl)lysine in Caco-2 cells. Ann. N.Y. Acad. Sci. 1126 (2008) 257-261
101. Cervantes-Laurean D., Roberts M.J., Jacobson E.L., and Jacobson M.K. Nuclear proteasome activation and degradation of carboxymethylated histones in human keratinocytes following glyoxal treatment. Free Radic. Biol. Med. 38 (2005) 786-795
102. Stolzing A., Widmer R., Jung T., Voss P., and Grune T. Degradation of glycated bovine serum albumin in microglial cells. Free Radic. Biol. Med. 40 (2006) 1017-1027
103. Hernebring M., Brolen G., Aguilaniu H., Semb H., and Nystrom T. Elimination of damaged proteins during differentiation of embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 7700-7705
104. Justilien V., Pang J.J., Renganathan K., et al. SOD2 knockdown mouse model of early AMD. Investig. Ophthalmol. Vis. Sci. 48 (2007) 4407-4420
105. Ma W., Lee S.E., Guo J., et al. RAGE ligand upregulation of VEGF secretion in ARPE-19 cells. Investig. Ophthalmol. Vis. Sci. 48 (2007) 1355-1361
106. McFarlane S., Glenn J.V., Lichanska A.M., Simpson D.A., and Stitt A.W. Characterisation of the advanced glycation endproduct receptor complex in the retinal pigment epithelium. Br. J. Ophthalmol. 89 (2005) 107-112
107. Tian J., Ishibashi K., Ishibashi K., et al. Advanced glycation endproduct-induced aging of the retinal pigment epithelium and choroid: a comprehensive transcriptional response. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 11846-11851
108. Cheng Y., and Gao M.H. The effect of glycation of CD59 on complement-mediated cytolysis. Cell Mol. Immunol. 2 (2005) 313-317
109. Munch G., Gasic-Milenkovic J., and Arendt T. Effect of advanced glycation endproducts on cell cycle and their relevance for Alzheimer's disease. J. Neural Transm., Suppl. (2003) 63-71
110. Hartog J.W., Voors A.A., Bakker S.J., Smit A.J., and van Veldhuisen D.J. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur. J. Heart Fail. 9 (2007) 1146-1155
111. Huijberts M.S., Schaper N.C., and Schalkwijk C.G. Advanced glycation end products and diabetic foot disease. Diabetes Metab. Res. Rev. 24 Suppl 1 (2008) S19-24
112. Jandeleit-Dahm K., Watson A., and Soro-Paavonen A. The AGE/RAGE axis in diabetes-accelerated atherosclerosis. Clin. Exp. Pharmacol. Physiol. 35 (2008) 329-334
113. Vasan S., Zhang X., Zhang X., et al. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 382 (1996) 275-278
114. Cheng R., Feng Q., Argirov O.K., and Ortwerth B.J. K2P-a novel cross-link from human lens protein. Ann. N.Y. Acad. Sci. 1043 (2005) 184-194
115. Monnier V.M., Mustata G.T., Biemel K.L., et al. Cross-linking of the extracellular matrix by the maillard reaction in aging and diabetes: an update on "a puzzle nearing resolution". Ann. N. Y. Acad. Sci. 1043 (2005) 533-544
116. Sell D.R., Biemel K.M., Reihl O., et al. Glucosepane is a major protein cross-link of the senescent human extracellular matrix. Relationship with diabetes. J. Biol. Chem. 280 (2005) 12310-12315
117. Price D.L., Rhett P.M., Thorpe S.R., and Baynes J.W. Chelating activity of advanced glycation end-product inhibitors. J. Biol. Chem. 276 (2001) 48967-48972
118. Yang S., Litchfield J.E., and Baynes J.W. AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats. Arch. Biochem. Biophys. 412 (2003) 42-46
119. Reddy V.P., and Beyaz A. Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases. Drug Discov. Today 11 (2006) 646-654
120. Canning P., Glenn J.V., Hsu D.K., et al. Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes. Exp. Diabetes Res. 2007 (2007) 51837
121. Bui B.V., Armitage J.A., Tolcos M., Cooper M.E., and Vingrys A.J. ACE inhibition salvages the visual loss caused by diabetes. Diabetologia 46 (2003) 401-408
122. Hughes J.M., Kuiper E.J., Klaassen I., et al. Advanced glycation end products cause increased CCN family and extracellular matrix gene expression in the diabetic rodent retina. Diabetologia 50 (2007) 1089-1098
123. Tilton R.G., Chang K., Hasan K.S., et al. Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 42 (1993) 221-232
124. Datta P., Kallur L., and Abraham E.C. Reversal of chaperone activity loss of glycated alphaA-crystallin by a crosslink breaker. Mol. Cell. Biochem. 315 (2008) 137-142
125. Oturai P.S., Christensen M., Rolin B., et al. Effects of advanced glycation end-product inhibition and cross-link breakage in diabetic rats. Metabolism 49 (2000) 996-1000
126. Ghavami S., Rashedi I., Dattilo B.M., et al. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J. Leukoc. Biol. 83 (2008) 1484-1492
127. Toure F., Zahm J.M., Garnotel R., et al. Receptor for advanced glycation end-products (RAGE) modulates neutrophil adhesion and migration on glycoxidated extracellular matrix. Biochem. J. 416 (2008) 255-261
128. Vincent A.M., Perrone L., Sullivan K.A., et al. Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. Endocrinology 148 (2007) 548-558
129. Yamagishi S., Matsui T., Nakamura K., et al. Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats. Ophthalmic Res. 39 (2007) 92-97
130. Soro-Paavonen A., Westerbacka J., Ehnholm C., and Taskinen M.R. Metabolic syndrome aggravates the increased endothelial activation and low-grade inflammation in subjects with familial low HDL. Ann. Med. 38 (2006) 229-238
131. Kaji Y., Usui T., Ishida S., et al. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Investig. Ophthalmol. Vis. Sci. 48 (2007) 858-865